Sociocultural variables have a major impact on participation in patients treated for paediatric posterior fossa tumours.
educational outcome
environmental predictor
late effects
paediatric central nervous system tumour
posterior fossa
risk factor
social participation
Journal
Child: care, health and development
ISSN: 1365-2214
Titre abrégé: Child Care Health Dev
Pays: England
ID NLM: 7602632
Informations de publication
Date de publication:
01 2023
01 2023
Historique:
revised:
21
03
2022
received:
24
09
2021
accepted:
13
06
2022
pubmed:
17
6
2022
medline:
16
12
2022
entrez:
16
6
2022
Statut:
ppublish
Résumé
This study investigates the severeness of participation barriers in patients surviving paediatric posterior fossa tumours (PFT) many years after treatment. In the past, aetiological studies on adverse outcome have primarily focused on pathobiological risk factors. The current analysis aims to investigate the importance of environmental variables. On average, 10 years after diagnosis, educational and social difficulties of 42 patients surviving paediatric PFT (mean age 17 years) were inquired using a self-constructed questionnaire following the Psychosocial Resource-Orientated Assessment (PREDI). Educational or social participation barriers were defined by self- and/or proxy-reported difficulties in school or in peer relationships. Accordingly, the children and adolescents were categorized into groups of adequate and limited participation. Subsequently, the study identified potential pathobiological (treatment type, hydrocephalus, tumour relapse, gender, age at diagnosis, seizures and cerebellar mutism) and environmental (parental and maternal education, siblings, main language, discrepancies between personal and environmental values, regular physical activity and private living space) risk factors and investigated whether patients with adequate and limited participation differed in the number of risk factors. Almost one decade after treatment, two thirds of patients experienced educational and/or social difficulties. Patients with limited participation were more frequently associated with environmental factors such as low maternal education degree, siblings, main language other than German, discrepancies between societal and personal values and irregular physical activity, as well as the pathobiological risk factors treatment type, hydrocephalus, tumour relapse, cerebellar mutism and seizures. These variables significantly discriminated between patients with and without limited participation. Limited participation in patients treated for paediatric PFT is common. Next to pathobiological, also environmental risk factors play a major role in educational and social participation barriers. This highlights the fact that solely considering pathobiology is not sufficient when investigating risk factors for the emergence of late sequelae. Future aetiological studies must adopt a biopsychosocial perspective.
Sections du résumé
BACKGROUND
This study investigates the severeness of participation barriers in patients surviving paediatric posterior fossa tumours (PFT) many years after treatment. In the past, aetiological studies on adverse outcome have primarily focused on pathobiological risk factors. The current analysis aims to investigate the importance of environmental variables.
METHODS
On average, 10 years after diagnosis, educational and social difficulties of 42 patients surviving paediatric PFT (mean age 17 years) were inquired using a self-constructed questionnaire following the Psychosocial Resource-Orientated Assessment (PREDI). Educational or social participation barriers were defined by self- and/or proxy-reported difficulties in school or in peer relationships. Accordingly, the children and adolescents were categorized into groups of adequate and limited participation. Subsequently, the study identified potential pathobiological (treatment type, hydrocephalus, tumour relapse, gender, age at diagnosis, seizures and cerebellar mutism) and environmental (parental and maternal education, siblings, main language, discrepancies between personal and environmental values, regular physical activity and private living space) risk factors and investigated whether patients with adequate and limited participation differed in the number of risk factors.
RESULTS
Almost one decade after treatment, two thirds of patients experienced educational and/or social difficulties. Patients with limited participation were more frequently associated with environmental factors such as low maternal education degree, siblings, main language other than German, discrepancies between societal and personal values and irregular physical activity, as well as the pathobiological risk factors treatment type, hydrocephalus, tumour relapse, cerebellar mutism and seizures. These variables significantly discriminated between patients with and without limited participation.
CONCLUSIONS
Limited participation in patients treated for paediatric PFT is common. Next to pathobiological, also environmental risk factors play a major role in educational and social participation barriers. This highlights the fact that solely considering pathobiology is not sufficient when investigating risk factors for the emergence of late sequelae. Future aetiological studies must adopt a biopsychosocial perspective.
Identifiants
pubmed: 35708465
doi: 10.1111/cch.13023
pmc: PMC10083959
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
106-118Informations de copyright
© 2022 The Authors. Child: Care, Health and Development published by John Wiley & Sons Ltd.
Références
J Neurooncol. 2015 Mar;122(1):161-8
pubmed: 25573605
Child Adolesc Psychiatry Ment Health. 2019 Sep 10;13:35
pubmed: 31528201
Oncol Nurs Forum. 2019 Mar 1;46(2):170-184
pubmed: 30767968
Pediatr Blood Cancer. 2011 Dec 15;57(7):1197-203
pubmed: 21294244
Epilepsy Behav. 2005 Dec;7(4):664-78
pubmed: 16140594
J Clin Oncol. 2018 Sep 20;36(27):2762-2769
pubmed: 30091946
Neuro Oncol. 2006 Jul;8(3):244-52
pubmed: 16723629
Dev Neurorehabil. 2022 Jan;25(1):19-28
pubmed: 33977851
Cerebellum. 2020 Feb;19(1):78-88
pubmed: 31832994
Clin Neuropsychol. 2011 Aug;25(6):942-62
pubmed: 21722062
Int J Radiat Oncol Biol Phys. 2013 Apr 1;85(5):1301-6
pubmed: 23245284
Neuro Oncol. 2012 Sep;14(9):1185-93
pubmed: 22898373
Child Care Health Dev. 2023 Jan;49(1):106-118
pubmed: 35708465
Lancet Oncol. 2016 Apr;17(4):484-495
pubmed: 26976201
Neuron. 2017 Sep 27;96(1):56-71
pubmed: 28957676
J Sports Sci Med. 2014 Sep 01;13(3):522-8
pubmed: 25177177
Neuro Oncol. 2017 May 1;19(5):689-698
pubmed: 28039368
PLoS One. 2012;7(10):e47944
pubmed: 23082232
Neuropsychiatr Dis Treat. 2013;9:1539-44
pubmed: 24133371
Child Neuropsychol. 2021 Jul;27(5):641-660
pubmed: 33596780
Psychooncology. 2013 Aug;22(8):1731-7
pubmed: 23059621
Brain. 2000 May;123 ( Pt 5):1041-50
pubmed: 10775548
Childs Nerv Syst. 2015 Oct;31(10):1877-90
pubmed: 26351237
Dev Neurorehabil. 2019 Jan;22(1):19-26
pubmed: 29336639
Curr Opin Pediatr. 2020 Apr;32(2):308-314
pubmed: 31895161
J Child Psychol Psychiatry. 1999 Jul;40(5):791-9
pubmed: 10433412
J Clin Oncol. 2013 Oct 1;31(28):3494-500
pubmed: 23980078
Brain. 1998 Apr;121 ( Pt 4):561-79
pubmed: 9577385
Int J Psychiatry Clin Pract. 2017 Jun;21(2):142-147
pubmed: 28498088
Nat Neurosci. 2015 May;18(5):773-8
pubmed: 25821911
Psychooncology. 2014 Oct;23(10):1157-64
pubmed: 24817624
Neuro Oncol. 2019 Aug 5;21(8):1069-1081
pubmed: 30793186
Scand J Psychol. 2018 Aug;59(4):392-406
pubmed: 29852055
Cancer. 2005 Oct 15;104(8):1751-60
pubmed: 16130127
J Am Acad Child Adolesc Psychiatry. 2020 Nov;59(11):1218-1239.e3
pubmed: 32504808
Neurosci Biobehav Rev. 2018 Dec;95:421-429
pubmed: 30273634
J Nat Sci Biol Med. 2014 Jul;5(2):233-9
pubmed: 25097389
J Clin Oncol. 2007 Nov 20;25(33):5262-6
pubmed: 18024873
Neuro Oncol. 2010 Dec;12(12):1311-7
pubmed: 20713408
Neuropsychology. 2009 Nov;23(6):705-17
pubmed: 19899829
Pediatr Blood Cancer. 2017 Sep;64(9):
pubmed: 28296130
Pediatr Neurol. 2014 Oct;51(4):515-21
pubmed: 25266614
JAMA Pediatr. 2015 Sep;169(9):822-9
pubmed: 26192216
J Clin Oncol. 2021 Jun 1;39(16):1795-1812
pubmed: 33886349
Qual Life Res. 1998 Jul;7(5):399-407
pubmed: 9691720
J Child Neurol. 2005 Mar;20(3):175-80
pubmed: 15832604
Childs Nerv Syst. 2016 Jul;32(7):1195-203
pubmed: 27142103
World Neurosurg. 2018 Jan;109:e594-e600
pubmed: 29054779
J Psychosoc Oncol. 2017 May-Jun;35(3):323-334
pubmed: 28300487
Child Care Health Dev. 2019 Mar;45(2):241-250
pubmed: 30693552
Demography. 2016 Jun;53(3):723-48
pubmed: 27173795
Epilepsia. 2011 Aug;52(8):1499-505
pubmed: 21569019
J Pediatr Psychol. 2020 Mar 1;45(2):194-202
pubmed: 31925436
Eur J Paediatr Neurol. 2014 Jul;18(4):469-74
pubmed: 24657012
Handb Clin Neurol. 2020;173:265-304
pubmed: 32958180